Dr. F. John Mills Joins Intelsius’ Board of Directors as Non-Executive Chair
Intelsius, a global manufacturer and distributor of environmentally safe, temperature-controlled and regulatory-compliant packaging solutions, announced today that it has appointed Dr. F. John Mills, MD, PhD, to the company’s board of directors as non-executive chair. Dr. Mills joins Intelsius with more than 25 years of executive and leadership experience in the pharmaceutical and biotech industries.
“I look forward to bringing my experience to Intelsius during such a time of global growth,” said Dr. Mills. “The company has all of the components for continued success in the global marketplace including an industry-experienced management team, strong product offerings, established partnerships and customer adoption and endorsement around the world.”
Dr. Mills is currently Chairman of the Board for BioStorage Technologies, a premier service provider of comprehensive sample management services for biological samples collected during clinical research. Mills co-founded the company in 2003 and also served as CEO before resigning from the position in late 2010. In 2009, Dr. Mills was appointed to the board of directors for ChanTest Corporation, a leading provider of cardiac safety, ion channel and GPCR services and products. In addition, Dr. Mills is a member of the board of directors for Bostech Corporation, a healthcare interoperability organization; and also serves as a strategic advisor to Popper and Company, an M&A advisory and specialty consulting firm.
Prior to founding BioStorage Technologies, Dr. Mills held roles of increasing responsibility at Covance, where he served as the Corporate Senior Vice President and President, Clinical Support Services. In addition to Covance, Dr. Mills has held senior management positions at Corning and Janssen Pharmaceutical.
“We greatly value Dr. Mills’ industry insight, knowledge of the global biotechnology and pharmaceutical industries, and specifically his expertise in temperature management technologies,” said David Walsh, founder and CEO of Intelsius. “We are excited he has elected to join our Board of Directors and we know his contributions and talents will make an enormous impact on our business moving forward.”
Dr. Mills received his M.D. from Cambridge University and his Ph.D. in endocrinology from Surrey University in the United Kingdom. He holds diplomas in pharmaceutical medicine, aviation medicine and marketing and has authored more than 40 scientific papers as well as a textbook on aviation medicine.
Incorporated in 1998, Intelsius is a subsidiary of DGP Life Science Ltd. Intelsius specializes in the design, manufacture and supply of temperature-controlled packaging and regulatory-compliant sample transport solutions. With a strong focus on developing environmentally sustainable products and procedures, the company offers eco-friendly ways to ensure the integrity of customers’ products and samples. Intelsius has a growing global presence, with manufacturing facilities, distribution hubs and local offices situated throughout the world, including North America, Europe and Asia.